First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up

被引：2

作者：

Shen, L. ^{[1
]}

Bai, Y. ^{[2
]}

Lin, X. ^{[3
]}

Li, W. ^{[4
]}

Wang, J. ^{[5
]}

Zhang, X. ^{[6
]}

Pan, H. ^{[7
]}

Bai, C. ^{[8
]}

Bai, L. ^{[9
]}

Cheng, Y. ^{[10
]}

Zhang, J. ^{[11
]}

Zhong, H. ^{[12
]}

Ba, Y. ^{[13
]}

Hu, W. ^{[14
]}

Xu, R. ^{[15
]}

Guo, W. ^{[16
]}

Qin, S. ^{[17
]}

Yang, N. ^{[18
]}

Lu, J. ^{[19
]}

Chanaga, C. Amaya ^{[20
]}

Soleymani, S. ^{[20
]}

Liu, T. ^{[21
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[2] Herbin Med Univ, Harbin, Heilongjiang, Peoples R China

[3] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China

[4] Jilin Univ, Hosp 1, Changchun, Peoples R China

[5] Henan Canc Hosp, Zhengzhou, Peoples R China

[6] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China

[7] Sir Run Shaw Hosp, Hangzhou, Peoples R China

[8] Peking Union Med Coll Hosp, Beijing, Peoples R China

[9] China PLA Gen Hosp, 301 Hosp, Beijing, Peoples R China

[10] Jilin Canc Hosp, Changchun, Peoples R China

[11] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

[12] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[13] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[14] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China

[15] Sun Yat Sen Univ, Med Oncol Canc Ctr, Guangzhou, Peoples R China

[16] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[17] Eastern Theater Gen Hosp, QinHuai Dist Med Area, Nanjing, Peoples R China

[18] Hunan Canc Hosp, Changsha Shi, Peoples R China

[19] Jiangsu Canc Hosp, Nanjing, Peoples R China

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.04.176

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-86

引用

页码：S279 / S279

页数：1

共 50 条

[1] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
Elimova, Elena
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
McCraith, Stephen
Liu, Tianshu
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
[3] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 353 - 353
[4] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Moehler, M.
Janjigian, Y. Y.
Shitara, K.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Bruges, R.
Cleary, J. M.
Karamouzis, M.
Soleymani, S.
Lei, M.
Amaya, Chanaga C.
Ajani, J. A.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
[5] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
[7] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Liu, Tianshu
[J]. CANCER RESEARCH, 2021, 81 (13)
[8] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
Lei, Ming
Janjigian, Yelena Y.
Ajani, Jaffer A.
Moehler, Markus
Wang, Xuya
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Li, Mingshun
Poulart, Valerie
Wang, Yu
Doshi, Parul
Shitara., Kohei
[J]. CANCER RESEARCH, 2022, 82 (12)
[9] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
[10] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Janjigian, Y. Y.
Ajani, J. A.
Moehler, M.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Li, M.
Poulart, V.
Lei, M.
Kondo, K.
Shitara, K.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330

← 1 2 3 4 5 →